PPP2R2A and non-small cell lung carcinoma: Thus, despite the complexity of PPP2R2A deficiency in the regulation of oncogenic signaling and cancer therapy in the different types of cancer, its impact on the increased sensitivity to CHK1 inhibition in NSCLC and HGSOC appears to be similar.